Ro vs Found Weight Loss 2026: GLP-1 Programs Compared
Ro vs Found for GLP-1 weight loss in 2026 — compare pricing, medications, provider experience, and clinical results. See how both stack up against Trimi's $99/mo semaglutide.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. We compare competitor programs to help patients make informed weight loss decisions.
Quick links: Semaglutide treatment, Ro semaglutide review, and Found semaglutide review.
More on GLP-1 Provider Comparisons
Ro vs Found: What You Need to Know
If you are comparing Ro vs Found for weight loss, you are evaluating two of the largest telehealth platforms offering GLP-1 receptor agonist medications in 2026. Both provide compounded semaglutide and tirzepatide through licensed pharmacies, but they differ meaningfully in pricing, coaching philosophy, and the overall treatment experience. Ro positions itself as a streamlined, pharmacy-first platform with competitive pricing, while Found emphasizes a holistic approach that combines medication with behavioral coaching and community support.
Definition: Ro (formerly Roman) and Found are telehealth platforms that prescribe GLP-1 receptor agonist medications — including compounded semaglutide and tirzepatide — for weight management. GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which reduces appetite, slows gastric emptying, and promotes satiety. Clinical trials have demonstrated 14.9% to 22.5% body weight reduction with these medications when combined with lifestyle modifications.
Ro (Ro Body) is one of the largest direct-to-consumer telehealth companies in the United States. Their weight loss program leverages an integrated pharmacy model — Ro owns its pharmacy operations, which allows tighter control over medication supply and potentially faster fulfillment. Ro offers asynchronous provider consultations, straightforward monthly pricing, and a no-frills approach that appeals to patients who primarily want accessible medication at a competitive price.
Found takes a different approach, branding itself as a comprehensive weight care platform. Found combines GLP-1 prescriptions with one-on-one behavioral coaching, community forums, and personalized treatment plans built around the premise that medication alone is insufficient for sustained weight loss. Their model attracts patients who want structured accountability and lifestyle support alongside their prescription.
Both platforms deliver legitimate GLP-1 treatment. The question is whether the differences in pricing and support justify choosing one over the other — and whether either offers better value than Trimi at $99 per month for compounded semaglutide.
Side-by-Side: Ro vs Found vs Trimi
The following table compares key features across all three platforms to help you evaluate which program best fits your needs and budget for GLP-1 weight loss treatment.
| Feature | Ro | Found | Trimi |
|---|---|---|---|
| Compounded Semaglutide | Yes | Yes | Yes |
| Compounded Tirzepatide | Yes | Yes | Yes |
| Behavioral Coaching | No | Yes (included) | Provider guidance |
| Community Support | No | Yes | No |
| Provider Communication | Async messaging | Messaging + coaching | Messaging + video |
| Pharmacy Model | Integrated (Ro Pharmacy) | Partner 503B pharmacies | Partner 503B pharmacies |
| Onboarding Speed | Fast (2-5 days) | Moderate (3-7 days) | Fast (2-5 days) |
| Contract Required | No | No (most plans) | Never |
| Free Shipping | Yes | Yes | Yes |
| Consultation Fee | Included | Included | Free |
| Insurance Accepted | No (cash-pay) | No (cash-pay) | No (cash-pay) |
Pricing Comparison: Ro vs Found vs Trimi
Cost is the most frequently cited factor when patients compare GLP-1 providers. Because these medications are used long-term — often 12 months or longer — even modest monthly differences compound into significant savings over time. Here is how Ro, Found, and Trimi's pricing compare in 2026.
| Cost Factor | Ro | Found | Trimi |
|---|---|---|---|
| Semaglutide (Monthly) | $99 - $199/mo | $129 - $199/mo | $99/mo |
| Tirzepatide (Monthly) | $199 - $349/mo | $199 - $299/mo | $125/mo |
| Consultation Fee | Included | Included | Free |
| Coaching Included | No (provider only) | Yes | Provider support |
| Shipping | Included | Included | Included |
| Contract Required | No | No (most plans) | Never |
| 6-Month Total (Sema) | $594 - $1,194 | $774 - $1,194 | $594 |
| 12-Month Total (Sema) | $1,188 - $2,388 | $1,548 - $2,388 | $1,188 |
| 6-Month Total (Tirz) | $1,194 - $2,094 | $1,194 - $1,794 | $750 |
| 12-Month Total (Tirz) | $2,388 - $4,188 | $2,388 - $3,588 | $1,500 |
For semaglutide, Ro's lowest tier matches Trimi's $99 per month, but their higher dosage tiers reach $199 per month. Found starts at $129 per month — $30 more than Trimi's flat rate. Over 12 months of tirzepatide treatment, Trimi saves $888 to $2,688 compared to Ro and $888 to $2,088 compared to Found. These are meaningful differences when treatment typically continues for a year or longer.
Price note: Telehealth GLP-1 pricing changes frequently. The figures above reflect published pricing as of April 2026. Promotional pricing, multi-month discounts, and tier changes may affect actual costs. Always confirm current pricing directly with each provider.
Medication Options: Semaglutide and Tirzepatide
The medications prescribed by Ro and Found are fundamentally the same. Both platforms offer compounded semaglutide and compounded tirzepatide manufactured by licensed 503B pharmacies under FDA oversight. The active pharmaceutical ingredients are identical — what differs is the surrounding service model and price.
| Medication Detail | Ro | Found | Trimi |
|---|---|---|---|
| Compounded Semaglutide | Yes | Yes | Yes |
| Compounded Tirzepatide | Yes | Yes | Yes |
| Pharmacy Type | Ro-owned 503B | Partner 503B | Partner 503B |
| Dose Titration Protocol | Provider-guided, standard | Coach + provider guided | Provider-guided |
| Oral GLP-1 Options | Some plans | Some plans | Injectable focus |
| B12/Levocarnitine Add-ons | Some formulations | Limited | Available |
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk and approved by the FDA under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management). Compounded versions contain the same active ingredient but are produced by 503B outsourcing facilities that operate under FDA registration and state pharmacy board oversight.
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved as Mounjaro (diabetes) and Zepbound (weight management). It acts on both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, which clinical trials suggest may produce greater weight loss than semaglutide alone. Both Ro and Found offer compounded tirzepatide, though at higher price points than semaglutide.
Provider Experience and Support
The treatment experience differs between Ro and Found in ways that matter to different types of patients. Understanding these differences helps you choose the platform that aligns with your preferences and support needs.
Where Ro Wins Over Found
Integrated pharmacy model means Ro controls supply chain from prescription to delivery — potentially fewer fulfillment delays
Simpler pricing structure with clear monthly rates and no tiered coaching plans to navigate
Faster onboarding for patients who want to start medication quickly without behavioral assessments
Lower entry price for semaglutide at $99/mo compared to Found's $129/mo starting point
Established telehealth infrastructure with millions of patients across multiple health verticals
No pressure to engage with coaching or community features — straightforward medication access
For a deeper look at Ro's approach, read our Ro semaglutide review and our guide on Ro weight loss side effects.
Where Found Wins Over Ro
Dedicated behavioral coaching included with medication — structured support for habit change and accountability
Community features connect patients on similar journeys for motivation and shared experience
More personalized treatment approach with comprehensive metabolic and behavioral assessments at intake
Emphasis on long-term behavioral change — not just pharmacological intervention but sustainable lifestyle modification
Broader medication toolkit historically, including non-GLP-1 options for patients who may benefit from different approaches
More frequent touchpoints between patients and their care team through coaching check-ins
For more on Found's program, see our Found semaglutide review and Found weight loss side effects guide.
Where Both Fall Short
Both cost more than Trimi's $99/mo semaglutide and $125/mo tirzepatide for the same compounded medications
Neither platform's higher pricing has been shown to produce better clinical outcomes than lower-cost providers
Both platforms bundle services into the price that not every patient needs or actively uses
Insurance does not cover either platform's compounded GLP-1 medications
Patients who leave either platform report that medication access — not coaching — was the primary value driver
Clinical Evidence Behind GLP-1 Weight Loss
Regardless of whether you choose Ro, Found, or Trimi, the medications themselves are supported by robust clinical evidence. Understanding the trial data helps you set realistic expectations for your weight loss journey.
Semaglutide: STEP 1 Trial Results
The landmark STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) established semaglutide 2.4 mg as a highly effective weight loss medication. In this 68-week, double-blind, randomized controlled trial involving 1,961 adults with obesity or overweight with at least one weight-related comorbidity, participants receiving semaglutide achieved a mean body weight reduction of 14.9% compared to 2.4% in the placebo group. Approximately one-third of participants lost 20% or more of their body weight — a threshold previously achievable only through bariatric surgery.
The most common side effects in the STEP 1 trial were gastrointestinal: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%). Most gastrointestinal events were mild to moderate in severity and occurred primarily during dose escalation. These side effects are relevant whether you receive semaglutide through Ro, Found, or any other provider — the medication profile does not change based on the prescribing platform.
Tirzepatide: SURMOUNT-1 Trial Results
The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) demonstrated that tirzepatide produced even greater weight loss than semaglutide in head-to-head comparisons. In this 72-week trial involving 2,539 adults with obesity, participants receiving the highest dose of tirzepatide (15 mg) achieved a mean body weight reduction of 22.5%. The 10 mg dose produced 21.4% mean weight loss, and the 5 mg dose produced 16.0% — all significantly exceeding placebo at 3.1%.
These results explain why tirzepatide has gained significant patient interest and why both Ro and Found now offer it alongside semaglutide. At Trimi, compounded tirzepatide is available at $125 per month — substantially less than Ro's $199 to $349 per month or Found's $199 to $299 per month.
What the Evidence Means for Platform Choice
Clinical trial outcomes depend on the medication and patient adherence — not on which telehealth platform prescribes the medication. A patient receiving compounded semaglutide through Trimi at $99 per month receives the same active pharmaceutical ingredient as a patient paying $199 per month through Ro or Found. The clinical evidence does not differentiate by provider. What the evidence does suggest is that long-term adherence matters enormously — and affordability is a primary driver of whether patients can sustain treatment long enough to achieve meaningful results.
Key statistic: The STEP 1 trial showed 14.9% mean body weight loss with semaglutide 2.4 mg over 68 weeks (Wilding et al., 2021). The SURMOUNT-1 trial showed 22.5% mean body weight loss with tirzepatide 15 mg over 72 weeks (Jastreboff et al., 2022). Both medications are available through Ro, Found, and Trimi.
Who Should Choose Which Provider?
Choose Ro If
You want an established telehealth platform with an integrated pharmacy, fast onboarding, and straightforward pricing. You are self-motivated and do not need structured behavioral coaching. You prefer a simple medication-focused program without community features or coaching upsells. Read more in our full Ro review.
Choose Found If
You value dedicated behavioral coaching alongside your medication and believe structured accountability will improve your long-term outcomes. You want community support from other patients on similar journeys. You are willing to pay a premium for a holistic weight management program that goes beyond medication alone. See our full Found review.
Choose Trimi If
You want the most affordable access to compounded semaglutide at $99 per month or tirzepatide at $125 per month with competent provider oversight, no contracts, and no hidden fees. You recognize that the medication itself — not the platform's extras — is the primary driver of weight loss results. You want to maximize your chances of sustaining treatment long-term by minimizing cost.
The Bottom Line: Ro vs Found for Weight Loss
Ro and Found both deliver legitimate GLP-1 weight loss treatment through well-established telehealth platforms. Ro offers a simpler, potentially faster experience with competitive pricing and an integrated pharmacy. Found offers more comprehensive behavioral support with coaching and community features. Both approaches have produced positive patient outcomes.
However, neither platform matches Trimi's value proposition. At $99 per month for compounded semaglutide and $125 per month for tirzepatide — with free consultations, free shipping, and no contracts — Trimi delivers the same clinically proven medications at the lowest price among major telehealth GLP-1 providers. The STEP 1 and SURMOUNT-1 clinical trials demonstrated that it is the medication itself that drives weight loss, not the platform wrapping around it. For most patients, choosing the provider that makes long-term treatment most financially sustainable is the best decision they can make.
Whether you are leaning toward Ro's streamlined approach or Found's coaching-intensive model, we recommend also exploring the cheapest GLP-1 options available in 2026 before committing. The savings over 12 months can be substantial — and those savings make it easier to stay on treatment long enough to reach your goals.
Frequently Asked Questions
Is Ro or Found better for GLP-1 weight loss?
Both Ro and Found offer effective GLP-1 weight loss programs through telehealth. Ro tends to be more affordable for semaglutide at $99 to $199 per month with a streamlined, pharmacy-integrated experience. Found charges $129 to $199 per month for semaglutide but includes behavioral coaching and community support. Neither is objectively better — it depends on whether you value lower pricing or structured coaching. However, Trimi offers compounded semaglutide at $99 per month with provider support, making it the most affordable option among major telehealth platforms.
How much does Ro cost compared to Found for semaglutide?
Ro charges $99 to $199 per month for compounded semaglutide depending on dosage and plan. Found charges $129 to $199 per month for semaglutide with coaching included. For tirzepatide, Ro charges $199 to $349 per month and Found charges $199 to $299 per month. Over 12 months, semaglutide treatment costs $1,188 to $2,388 at Ro and $1,548 to $2,388 at Found. Trimi's $99 per month totals $1,188 for the year — matching Ro's lowest tier and saving $360 to $1,200 compared to Found.
Does Found include coaching that Ro does not?
Yes, Found includes personalized behavioral coaching as part of their weight loss programs. Ro provides provider consultations and messaging-based support but does not offer dedicated behavioral coaching. Whether coaching justifies the price difference depends on your needs — many patients achieve strong results with medication and standard provider guidance alone, without paying extra for structured coaching programs.
Which platform prescribes better GLP-1 medications?
Both Ro and Found provide compounded semaglutide and tirzepatide manufactured by licensed 503B pharmacies. The active ingredients are identical regardless of which platform prescribes them. Differences between Ro and Found lie in pricing, provider experience, and ancillary services — not medication quality. Trimi also provides the same compounded medications at lower price points.
Can I switch from Ro to Found or from Found to Ro?
Yes, you can switch between Ro and Found at any time. Both platforms offer month-to-month plans without long-term contracts for most tiers. You will need to complete a new medical intake with the new provider, which may cause a brief gap in treatment. Before switching, consider comparing both to Trimi at $99 per month for semaglutide or $125 per month for tirzepatide.
Do Ro and Found accept insurance for GLP-1 medications?
Neither Ro nor Found typically accepts insurance for their compounded GLP-1 medication programs. Both platforms operate on a cash-pay model. Some patients may be able to use HSA or FSA funds. Trimi also uses a cash-pay model at $99 per month for semaglutide — often less than what insurance copays would cost for brand-name Wegovy or Ozempic.
What is cheaper than both Ro and Found for GLP-1 weight loss?
Trimi offers compounded semaglutide at $99 per month and tirzepatide at $125 per month — the lowest pricing among major telehealth GLP-1 providers. This includes free consultations, free shipping, and no contracts. Over 12 months, Trimi saves up to $1,200 compared to Ro's higher tiers and up to $1,200 compared to Found for the same compounded semaglutide.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed.
- Ro telehealth platform and weight loss program pricing (2026).
- Found weight loss program and pricing (2026).
- FDA guidance on drug compounding and 503B outsourcing facilities.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any weight loss medication. GLP-1 receptor agonists carry risks and are not appropriate for all patients. Trimi is a competitor to both Ro and Found — readers should be aware of our perspective when evaluating these comparisons.